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Background: There is increasing evidence for the role of impaired intestinal permeability 
in obesity and associated metabolic diseases. Zonulin is an established serum marker for 
intestinal permeability and identical to pre-haptoglobin2. Here, we aimed to investigate 
the relationship between circulating zonulin and metabolic traits related to obesity.
Methods: Serum zonulin was measured by using a widely used commercial ELISA kit in 
376 subjects from the metabolically well-characterized cohort of Sorbs from Germany. In 
addition, haptoglobin genotype was determined in DNA samples from all study subjects.
results: As zonulin concentrations did not correlate to the haptoglobin genotypes, 
we investigated the specificity of the zonulin ELISA assay using antibody capture 
experiments, mass spectrometry, and Western blot analysis. Using serum samples that 
gave the highest or lowest ELISA signals, we detected several proteins that are likely 
to be captured by the antibody in the present kit. However, none of these proteins 
corresponds to pre-haptoglobin2. We used increasing concentrations of recombinant 
pre-haptoglobin2 and complement C3 as one of the representative captured proteins 
and the ELISA kit did not detect either. Western blot analysis using both the polyclonal 
antibodies used in this kit and monoclonal antibodies rose against zonulin showed a 
similar protein recognition pattern but with different intensity of detection. The protein(s) 
measured using the ELISA kit was (were) significantly increased in patients with diabetes 
and obesity and correlated strongly with markers of the lipid and glucose metabolism. 
Combining mass spectrometry and Western blot analysis using the polyclonal antibodies 
used in the ELISA kit, we identified properdin as another member of the zonulin family.
conclusion: Our study suggests that the zonulin ELISA does not recognize pre-hap-
toglobin2, rather structural (and possibly functional) analog proteins belonging to the 
mannose-associated serine protease family, with properdin being the most likely possible 
candidate.
Keywords: diabetes, lipid metabolism, precursor of haptoglobin2, elisa, intestinal permeability, properdin, 
obesity, metabolic diseases
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inTrODUcTiOn
The “intestinal barrier” is an established term, defined as a func-
tional entity separating the gut lumen from the inner host, and 
consisting of mechanical, humoral, immunological, muscular, 
and neurological elements. Intestinal barrier dysfunction is a 
characteristic feature of pathological states such as inflammatory 
bowel disease, celiac disease, nonalcoholic steatohepatitis, and 
ulcerative colitis (1, 2). There is also emerging evidence for the 
role of impaired intestinal permeability in metabolic diseases 
including obesity and type 2 diabetes (T2D) (3–5). It has been 
hypothesized that gut bacteria and bacterial endotoxins may 
disrupt the intestinal barrier resulting in the so-called “leaky gut” 
(4, 6). The leakage of toxins, bacterial components or even live 
bacteria, and their transfer to target organs such as adipose tissue 
might contribute to the development of obesity and T2D (6, 7). 
Indeed, numerous studies in mouse models have demonstrated 
that changes in the gut microbiota can alter the gut permeability 
and lead to an endotoxemia-induced inflammation in adipose tis-
sue, and ultimately to obesity (3, 8, 9). Results from experimental 
mouse models are supported by studies in humans by showing 
an increase in circulating endotoxin levels and circulating bacte-
rial DNA in obese/diabetic patients, likely due to an increased 
intestinal permeability in affected subjects (10, 11).
Intestinal barrier transport is mainly regulated by structures 
of the paracellular pathway called tight junctions which form 
barriers between epithelial cells and regulate the transport of 
ions and small molecules across the intestinal lumen. Intestinal 
permeability is a functional feature of the intestinal barrier. It can 
be measured by analyzing flux rates of inert molecules across the 
intestinal wall as a whole or across wall components (1). The gold 
standard for assessment of intestinal permeability in vivo is an 
assay combining indigestible large and small oligosaccharides, 
such as lactulose and mannitol; the larger oligosaccharide, lactu-
lose, is only transported via the paracellular pathway, whereas 
the smaller oligosaccharide, mannitol, is taken up freely over 
the intestinal barrier via the transcellular route. However, these 
oligosaccharide assays are expensive, laborious, poorly reproduc-
ible, and time-consuming. Therefore, identifying appropriate bio-
markers for intestinal permeability is highly desirable. Zonulin 
has been identified as a tight junction regulating protein which 
is, functionally, the human counterpart of the Vibrio cholera 
endotoxin zonula occludens toxin (12, 13). Precisely, subsequent 
studies recognized zonulin as the precursor of haptoglobin2 
(pre-HP2) (14). HP is a well-known protein involved in scaveng-
ing hemoglobin, whereas the function of its precursor is largely 
unknown. HP is first synthesized into a single-chain precursor 
protein, which is cleaved into a light N-terminal α-chain and 
heavy C-terminal β-chain. An exon duplication of exons 3 and 
4 of the HP gene differentiates the HP1 from the HP2 allele. 
Due to this exon duplication, the HP2 α-chain is 1.7 kb longer 
than in the HP1 allele. HP is active as tetramer consisting of 2 
α- and 2 β-chains linked by disulfide bonds, resulting in three 
possible genotypes: homozygous HP1/1, homozygous HP2/2, 
and heterozygous HP1/2 (15, 16). About 15% of the Caucasian 
population is homozygous for HP (16, 17). Zonulin as pre-HP2 
reversibly opens tight junctions and is upregulated in diseases 
such as celiac disease and type 1 diabetes (14, 18). Serum zonulin 
concentrations are also increased in T2D and obesity (19–21) and 
strong correlations were observed with various metabolic mark-
ers, including fasting plasma glucose, IL-6, HDL, and triglyceride 
(TG) levels (19–21).
Here, we aimed at characterizing the relationship between 
circulating serum zonulin and traits related to obesity in a 
metabolically well-characterized cohort of Sorbs from Germany. 
To measure zonulin, we used the commercially available ELISA 
kit (Immundiagnostik, Bensheim, Germany). In addition, we 
determined the HP genotypes in the entire cohort. Due to a lack 
of correspondence between the observed circulating zonulin 
concentrations and the HP genotypes in our study cohort, we 
further investigated the possible identity of the product captured 
by the commercial ELISA assay. We found that the ELISA kit used 
in the present study does not detect purified pre-HP2 but rather 
targets one or more proteins from a range of candidate molecules 
possibly structurally and functionally related to zonulin. Our data 
also showed that protein concentrations measured by this ELISA 
correlated with parameters of obesity and related metabolic traits.
MaTerials anD MeThODs
study subjects
All subjects are part of a sample from an extensively clinically 
characterized population from Eastern Germany, the Sorbs 
(22–24). Extensive phenotyping included standardized question-
naires to assess past medical history and family history, collec-
tion of anthropometric data [weight, height, waist-to-hip ratio 
(WHR)], and an oral glucose tolerance test. Glucose was assessed 
by the Hexokinase method (Automated Analyzer Modular, 
Roche Diagnostics, Mannheim, Germany) and serum insulin was 
measured using the AutoDELFIA Insulin assay (PerkinElmer Life 
and Analytical Sciences, Turku, Finland). Total serum cholesterol 
and TG concentrations were measured by standard enzymatic 
methods (CHOD-PAP and GPO-PAP; Roche Diagnostics). 
Serum LDL-C and HDL-C concentrations were determined 
using commercial homogeneous direct measurement methods 
(Roche Diagnostics). All assays were performed in an automated 
clinical chemistry analyzer (Hitachi/Roche Diagnostics) at the 
Institute of Laboratory Medicine, University Hospital Leipzig.
All blood samples were taken in the morning after an overnight 
fast and stored at −80°C until analyses. From the 1,040 Sorbs 
enrolled in the cohort, a subgroup of 376 subjects was genotyped 
for HP and provided blood samples for zonulin measurements 
(Table 1). Main metabolic characteristics of the study subjects are 
summarized in Table 2.
The study was approved by the ethics committee of the 
University of Leipzig and all subjects gave written informed 
consent before taking part in the study.
elisa Measurements
Circulating zonulin was measured by a competitive ELISA 
(Immundiagnostik AG, Bensheim, Germany) in serum samples Abbreviations: HP, haptoglobin; T2D, type 2 diabetes; WHR, waist-to-hip ratio.
TaBle 2 | Main characteristics of the study participants.
ngT igT T2D
n 191 79 106
Age (years) 45.4 ± 15.6 59.7 ± 29.4** 62.9 ± 11.2**
BMI (kg/m2) 25.8 ± 5 29.7 ± 4.6** 30.97 ± 5.53**
WHR 0.84 ± 0.10 0.92 ± 0.09 0.94 ± 0.09**
FPG (mmoL/L) 5.15 ± 0.50 5.68 ± 0.56** 7.72 ± 2.43**°°
120-min PG 
(mmoL/L)
5.00 ± 1.40 8.95 ± 0.98** 5.78 ± 6.86°°
Triglycerides 
(mmoL/L)
1.29 ± 0.94 1.56 ± 0.92* 1.87 ± 1.24**
Fasting insulin 
(pmoL/L)
35.90 ± 25.98 53.56 ± 25.98** 62.38 ± 43.07**
120-min insulin 
(pmoL/L)
148.39 ± 133.58 409.28 ± 232.81** 182.22 ± 272.34°°
HDL (mmoL/L) 1.69 ± 0.40 1.56 ± 0.36* 1.43 ± 0.39**°
LDL (mmoL/L) 3.20 ± 0.96 3.70 ± 1.06** 3.33 ± 0.95°
Total cholesterol 
(mmoL/L)
5.12 ± 1.03 5.57 ± 1.18* 5.27 ± 0.99
HOMA IR (pmoL/
L*mmoL/L)
1.34 ± 1.06 2.30 ± 1.1** 3.58 ± 2.87**°°
HOMA IS (ratio) 1.07 ± 0.76 0.67 ± 0.78** 0.68 ± 1.63**
CRP (mg/L) 2.22 ± 4.20 3.19 ± 4.54 3.87 ± 4.76**
Zonulin (ng/mL) 67.25 ± 25.45 71.88 ± 29.36 81.78 ± 25.31**°°
* p < 0.05 vs NGT; ** p < 0.01 vs. NGT.
° p < 0.05 vs. IGT; °° p < 0.01 vs. IGT.
All data given as mean ± SD. NGT, normal glucose tolerance; IGT, impaired glucose 
tolerance; T2D, type 2 diabetes; CRP, C-reactive protein; HDL, high-density lipoprotein; 
LDL, low-density lipoprotein; FPG, fasting plasma glucose; WHR, waist-to-hip ratio.
TaBle 1 | Composition of the study cohort included in zonulin measurements.
all Female Male
n 376 233 143
Age (years) 53.3 ± 16.2 52.7 ± 15.8 54.2 ± 16.8
BMI (kg/m2) 28.1 ± 5.6 27.9 ± 5.9 28.5 ± 5.1
NGT 191 (50.8%) 124 (53.2%) 67 (46.8%)
IGT 79 (21.0%) 49 (21.0%) 30 (21.0%)
T2D 106 (28.2%) 60 (25.8%) 46 (32.2%)
Age and BMI are mean ± SD, NGT, IGT, and T2D as absolute number (percentage). 
NGT, normal glucose tolerance; IGT, impaired glucose tolerance; IFG, impaired fasting 
glucose.
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of 376 individuals according to the manufacturer’s protocol. Inter-
assay coefficient of variation was 6.5%. When purified proteins 
zonulin and properdin and the synthetic peptide AT1001 were 
tested by the ELISA, they were resuspended in PBS and diluted in 
Diluent buffer (IDK kit) to reach a final concentration of 5 µg/mL.
genotyping
Haptoglobin genotypes were determined by PCR using a method 
adapted from Koch et al. (17). Briefly, the following two primer 
pairs were used: A (5′-GAGGGGAGCTTGCCTTTCCATTG-3′) 
and B (5′-GAGATTTTTGAGCCCTGGCTGGT-3′), as well as C 
(5′-CCTGCCTCGTATTAACTGCACC AT-3′) and D (5′-CCGAG 
TGCTCCACATAGCCATGT-3′). For primer pair A/B, a 95°C initial 
denaturation was done for 5 min followed by 35 cycles of 95°C 
(20  s) denaturation, 58°C (30  s) primer annealing, and 69°C 
(3.5 min) elongation. A terminal elongation of 7 min at 72°C was 
included at the end. For the primer pair C/D, conditions were as 
follows: 95°C for 5 min; 35 cycles of 95°C for 30 s and 69°C for 2 
min; and 7 min at 72°C.
The primer pair A/B generates two bands: a 1,757-bp allele-1 
specific band and a 3,481-bp allele-2 specific band. The primer 
pair C/D produces one allele-2 specific band of 349  bp. The 
combination of the bands allows a reproducible typing of the two 
common HP genotypes HP1 and HP2. In contrast, no band is 
detectable for the rare HP deletion genotype, present in ~0.1% 
Caucasians (16).
antibody capturing experiment
We aimed to isolate the target protein of the ELISA antibody 
from serum samples utilizing the immobilized anti-zonulin 
antibodies on the ELISA plates to perform antibody captur-
ing experiments. Based on the manufacturing information, 
these polyclonal antibodies were raised against an octapeptide 
sequenced from the zonulin molecule (25). Equal amounts of 
undiluted serum samples with highest and lowest concentra-
tions of zonulin, as measured using the same ELISA kit, were 
transferred to separate wells, incubated, and washed according to 
the manufacturer’s protocol. Afterward, we eluted the captured 
protein(s) by incubation with 50 µL of hot (95°C) SDS sample 
buffer with β-mercaptoethanol for 5 min. The captured protein 
of high- or low-zonulin serum samples were pooled [N = 8 for 
high (two pooled groups) and low (one pooled group); measured 
protein concentrations using the zonulin ELISA of the serum 
samples is given in Table S1 in Supplementary Material]. In 
addition, 20 µL of these elution samples (high or low zonulin) 
were separated by SDS-PAGE using precast Bolt 4–12% Bis-Tris 
Plus gels (ThermoFisher, Waltham, MA, USA). Proteins were 
stained using the Pierce silver stain for mass spectrometry 
(ThermoFisher) or detected by Western Blot.
Mass spectrometry
To identify proteins isolated from serum samples as described 
above, bands were excised from silver-stained gels and in-gel 
digested with trypsin following a standard protocol (26). After 
enzymatic digestion, the peptide mixtures were immediately 
analyzed by LC/MS/MS on an U3000 RSLC nano-HPLC system 
(Thermo Fisher Scientific) coupled to an Orbitrap Fusion Tribrid 
mass spectrometer (Thermo Fisher Scientific). Samples were 
loaded onto a pre-column (RP-C8, 300 µm * 5 mm, 5 µm, 100 Å, 
Thermo Fisher Scientific) and washed with water containing 
0.1% (v/v) TFA for 15 min, before the peptides were separated on 
the separation column (RP-C18, 75 µm * 250 mm, 2 µm, 100 Å, 
Thermo Fisher Scientific) using gradients from 1 to 40% (v/v) B 
(45 min) and 40 to 85% (v/v) B (5 min) followed by 85% B (5 min), 
with solvent A: 0.1% (v/v) formic acid (FA) in water and solvent 
B: 0.08% (v/v) FA in acetonitrile. Data were acquired using data-
dependent MS/MS mode where each high-resolution full-scan 
in the orbitrap (m/z 198–1,500; R =  120,000) was followed by 
high-resolution product ion scans in the orbitrap [higher energy 
collision-induced dissociation (HCD), 27% normalized collision 
FigUre 1 | Distribution of zonulin ELISA values according to haptoglobin 
genotypes. Data are presented as boxplots with Turkey–Whiskers and 
outliers.
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energy, R = 15,000, isolation window 2 Th] within 5 s, starting 
with the most intense signal in the full-scan mass spectrum.
Data analysis was performed using the Proteome Discoverer 
2.1 (Thermo Fisher Scientific). MS/MS data of precursor ions (m/z 
range 350–5,000) were searched against the Swissprot Database 
(version 11/2016, taxonomy human, 20,082 entries) and a con-
taminant database using Sequest HT. Mass accuracy was set to 
5 ppm and 20 mmu for precursor and fragment ions, respectively. 
Carbamidomethylation of cysteines was set as fixed modification, 
oxidation of methionines and N-terminal acetylation were set as 
variable modifications, and two missed cleavages of trypsin were 
allowed. Results were filtered for non-contaminant proteins iden-
tified by at least three unique highly confident peptides (peptide 
FDR ≤ 1%).
Western Blot analysis
Western blot experiments were performed to validate the results 
of mass spectrometric data analysis and to compare the serum 
target proteins identified by the polyclonal antibodies used by 
this ELISA kit compared with monoclonal anti-zonulin anti-
bodies. Gels were blotted on a PVDF membrane and Western 
blots were probed with anti-C3 β-chain (1:2,000) (Biozol, 
Eching, Germany), anti-HP (1:1,000) (Abcam, Cambridge, 
UK), polyclonal anti-zonulin (1:500) (kindly provided by 
Immundiagnostik), and monoclonal anti-zonulin (1:5,000) 
(BioRad, Hercules, CA, USA) antibodies. Purified C3c from 
plasma (Athens Research, Athens, GA, USA) and recombi-
nant zonulin were used as positive controls. Properdin (R&D 
Systems, Minneapolis, MN, USA) was also used to validate the 
potential protein candidate identified by the ELISA. Incubation 
with primary and secondary antibodies (HRP-conjugated) was 
done for 90 min at room temperature. Blots were visualized 
by enhanced chemiluminescence using Pierce ECL Western 
Blotting Substrate (ThermoFisher Scientific).
statistical analysis
Statistical analysis was performed using SPSS 24 (IBM). All non-
normally distributed metric parameters were log transformed 
to generate a Gaussian normal distribution. Spearman’s rank 
correlation method was used to assess the relationship between 
metabolic traits. To test for significant differences in distribution 
for ordinal values, the Kruskal–Wallis test was used. Exact differ-
ences between two groups were tested by both the Mann–Whitney 
U test and unpaired Student’s t-test. In addition, multiple linear 
regression analyses were done to assess the linear relationship 
between continuous variables and genotypes. For all tests, a value 
of p < 0.05 was considered to be statistically significant.
resUlTs
haptoglobin genotype
Haptoglobin genotype HP1/1 was present in 15.8% of the sub-
jects, HP1/2 in 47.6%, and HP2/2 in 36.6%. These frequencies 
are comparable with the distribution of HP genotypes in cohorts 
of European ancestry reported by others (16, 17). We tested the 
association of the HP genotypes with various anthropometric 
and metabolic traits in all study subjects. The analysis revealed 
that blood hemoglobin levels significantly increase with the 
presence of at least one HP2 allele (p =  0.004 over all three 
groups, p =  4.2  ×  10−4 between HP1 homozygote and HP2 
carriers). Furthermore, we observed that the total protein 
concentration in the urine significantly differed between the 
three groups, with an increase in the HP2 carriers (p = 0.027). 
Interestingly, mean triiodothyronine (fT3) levels were lower 
in the HP1/1 group than in the HP2/2 group (p = 0.012) and 
in accordance, an increase in administered thyroid gland hor-
mones (p = 0.023) was observed.
Zonulin elisa Data not Matching hP 
genotype Distribution
Strikingly, there were no significant differences in levels of the 
zonulin ELISA signal between the three HP genotype groups 
(Figure  1; p =  0.153 using ANOVA, p =  0.07 for the t-test 
comparing log-transformed zonulin signals between HP1/1 
vs. HP1/2  +  HP2/2). Assuming that the protein measured 
by the kit is zonulin (i.e., pre-HP2), subjects with the HP1/1 
genotype were expected to have no detectable zonulin levels. 
As the zonulin concentrations measured in patient sera using 
the zonulin ELISA kit clearly did not reflect the HP genotype 
distribution, we therefore concluded that the protein measured 
by the kit is not identical to zonulin as pre-HP2 or that, beside 
pre-HP2, the kit detects other unrelated proteins. Consequently, 
we aimed at identifying the protein(s) detected by the alleged 
zonulin ELISA kit.
FigUre 2 | (a) Silver stain of immunoprecipitated ELISA products and (B) Western blot analyses using an anti-C3 β-chain antibody. Commercially available C3c 
protein isolated from human plasma was run as positive control. High: pooled IP samples of sera that gave highest ELISA signals; low: pooled IP samples of sera 
that gave lowest ELISA signals; neg: negative control using dilution buffer from the ELISA kit; tracer: competitive tracer reagent from the ELISA kit. Letters in (A) 
indicated bands analyzed by MS after tryptic in gel digestion (Table S2 in Supplementary Material).
5
Scheffler et al. Zonulin ELISA Detects Also Properdin
Frontiers in Endocrinology | www.frontiersin.org February 2018 | Volume 9 | Article 22
The Zonulin elisa Does not Detect 
recombinant pre-hP2, but Targets 
Multiple Proteins
To attempt identifying proteins bound and quantified by the 
capturing antibody deployed in the zonulin ELISA kit, we 
performed an immune-capturing experiment using patient sera 
and the immobilized antibody of the ELISA kit as supplied. After 
incubation of the immobilized ELISA kit antibodies with selected 
patient sera representing the highest and lowest measured ELISA 
signals in the cohort, the captured proteins were separated by 
SDS-PAGE. Notably, we could not measure the protein content 
of the eluted samples, but given that equal amounts of serum were 
used, that the same washing and elution procedure was performed 
for all samples, and that 20 µL of the pooled elution samples were 
used for SDS-PAGE and Western blot, the detected amount of 
“captured” protein should resemble the amount of protein that 
was present in the initial serum sample.
Silver staining revealed multiple bands, with the most intense 
band at ~70  kDa and further prominent bands at ~55, ~180, 
and >180  kDa (Figure  2A). This band pattern was incompat-
ible with a band pattern that would be expected for pre-HP2 
or HP-derived proteins and further supported the results dem-
onstrating the lack of correspondence of the captured protein 
with HP genotypes. To further characterize major proteins 
captured by the ELISA kit, protein bands were cut (Figure 2A) 
and subjected to MS analysis after tryptic digestion (Table S2 in 
Supplementary Material). Mass spectrometry demonstrated that 
bands 1 (>180 kDa), 2 (~150 kDa), and 3 (~70 kDa) were all very 
likely representing the C3 protein or cleavage products derived 
from the C3 protein, such as the C3 precursor (187 kDa), C3c 
(144 kDa), and the C3 β-chain (71 kDa). Furthermore, the 55 kDa 
band was identified as properdin or factor P (MW 53 kDa). To 
validate results from mass spectrometry, we performed Western 
blot analyses. The major band at 70 kDa was clearly detected by 
an anti-C3 β-chain antibody (Figure 2B).
Consequently, we tested several C3c proteins from different 
suppliers (Abcam, Cambridge, UK; Athens Research, Athens, 
GA, USA; mybiosource, San Diego, CA, USA), in a range from 
0.1 mg/mL to 0.1 ng/mL under native and denatured conditions, 
as well as diluted in serum, with the respective ELISA kit. All 
results were negative (data not shown), indicating that C3 might 
represent a contaminant only. Additionally, we tested C3, recom-
binant zonulin, HP1, and HP2 at increasing concentrations (range 
1–50 µg/mL), along with sera from celiac patients (both HP1-1 
and HP2-2), healthy controls (both HP1-1 and HP2-2), and our 
standard control (AF, HP2-2). The results showed in Figure  3 
demonstrated that while this kit does not recognize C3, zonulin, 
or mature HP (both HP1 and HP2), it does recognize protein(s) 
both in HP1-1 and HP2-2 genotype subjects, irrespective of their 
disease status.
anti-zonulin Monoclonal antibodies and 
immundiagnostik Polyclonal antibodies 
recognizing the same Target Proteins in 
Western Blot
Our ELISA results clearly showed that this kit does not detect 
zonulin (alias, pre-HP2 as originally claimed by the manufac-
turer) or complement C3, the protein captured by our experi-
ments described above. In order to further characterize the target 
protein(s) of this kit, we performed Western blotting analysis of 
sera from an HP2-2 subject either under baseline condition or 
after deglycosylation as we have previously described (14), using 
recombinant zonulin as control. As anticipated, the zonulin 
monoclonal antibodies recognized recombinant zonulin as well 
as a variety of bands in the serum sample, including bands with a 
MW of ~70, 52, 37, 27, and 16 kDa (Figure 4A). Based on similar 
patterns we detected when zonulin was originally cloned (14), we 
predicted that the ~72 kDa corresponded to the glycosylated HP 
β-chain, the 52 kDa zonulin, and the 16 kDa the HP2 α-chain. 
To confirm this interpretation, we performed deglycosyla-
tion experiments showing the shift of the 72-kDa β-chain to a 
lower MW, while, as anticipated, the zonulin band and the HP2 
α-chain remained unchanged (Figure 4A). Interestingly enough, 
the Immundiagnostik polyclonal antibodies raised against the 
zonulin synthetic peptide inhibitor GGVLVQPG (AT1001) (25) 
recognized the same main bands detected by the monoclonal 
antibodies but with different intensity, being the recombinant 
zonulin and serum α-chain bands fainter compared with the 
monoclonal antibody signal, while the serum β-chain and serum 
zonulin-like signals stronger (Figure 4A). When combined to our 
FigUre 4 | Western blot analyses of a prototype human serum sample (AF HP2-2) using both anti-zonulin monoclonal antibodies and Immundiagnostik polyclonal 
antibodies. (a) Prototype serum sample of an HP2-2 homozygous subject, either untreated (lane 1) or after deglycosylation (lane 2) was resolved and then 
immunoblotted using either anti-zonulin monoclonal antibodies (left panel) or Immundiagnostik polyclonal antibodies (right panel). Recombinant zonulin was added 
as control (lane 3). As anticipated, zonulin monoclonal antibodies recognize the recombinant protein as well as a serious of serum bands, with the strongest signal 
being related to the 16-kDa zonulin α2-chain. The Immundiagnostik polyclonal antibodies also recognize recombinant zonulin but with a much weaker signal 
compared with the monoclonal antibodies. These antibodies also recognize the same serum bands detected by the zonulin monoclonal antibodies, with the 
~70- and 52-kDa bands being highlighted with the strongest signal. Sample’s deglycosylation showed the shift of the 70-kDa band to a lower MW, suggesting that 
this may represent the zonulin β-chain as we have previously shown (14). (B) Prototype serum samples of an HP1-1 and an HP2-2 homozygous subject were 
resolved and immunoblotted using the Immundiagnostik polyclonal antibodies. Recombinant zonulin and properdin were added as control. The antibodies also 
detect properdin that migrated at the same molecular weight of zonulin and serum bands recognized by the antibodies in both HP2-2 and HP1-1 subjects.
FigUre 3 | Mean zonulin ELISA values obtained by testing specific candidate target proteins and patients’ serum samples. This ELISA kit did not detect increasing 
concentrations (range 1–50 µg/mL) of complement, recombinant zonulin (pre-HP2), mature HP1 or mature HP2. Conversely, a strong signal was detected in sera of 
both celiac disease patients (CD) and healthy controls (non-CD, internal control AF with HP2-2), irrespective of their HP genotype. All samples were measured in 
technical triplicates; kit controls are shown for comparison.
6
Scheffler et al. Zonulin ELISA Detects Also Properdin
Frontiers in Endocrinology | www.frontiersin.org February 2018 | Volume 9 | Article 22
FigUre 5 | (a) Mean zonulin ELISA values according to glucose tolerance groups (B) mean ELISA values according to BMI groups. ** p < 0.01; *** p < 0.001. 
NGT, normal glucose tolerance; IGT, impaired glucose tolerance; T2D: type 2 diabetes.
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ELISA results, these data suggest that while the zonulin monoclo-
nal antibodies specifically detect in serum samples only zonulin 
at its predicted molecular weight, most likely the polyclonal 
antibodies used in this kit are possibly detecting “zonulin-like” 
protein(s) (as suggested by the much more intense signal of the 
~52-kDa band compared with the monoclonal antibodies) with 
similar molecular weight, structure, and possibly function.
immundiagnostik Polyclonal antibodies 
recognizing both Pre-hP2 and Properdin 
as an additional Target in Western Blot
Among all the proteins we identified with our mass spec analy-
sis, properdin fulfills the structural–functional characteristics 
mentioned above and, therefore, may represent the most likely 
candidate target detected by this ELISA kit. To explore this 
hypothesis, we performed both Western blotting analysis using the 
Immunodiagnostik polyclonal antibodies and ELISA test using 
commercially available properdin. The Western blot showed that 
beside recombinant zonulin, the Immunodiagnostik polyclonal 
antibodies also detect properdin (Figure 4B) that migrated at the 
same molecular weight of zonulin and serum bands recognized 
by the antibodies in both HP2-2 and HP1-1 subjects (Figure 4B). 
Similar results were obtained with polyclonal antibodies raised 
against recombinant zonulin (data not shown). The same samples 
used for Western blotting analysis, including zonulin, properdin, 
and AT1001 at a concentration of 5 µg/mL were tested using the 
ELISA kit. The results showed that properdin and AT1001 were 
both detected by the ELISA test; however, their amounts were 
substantially underestimated by 914- (5.47 ng/mL) and 40-folds 
(126.04 ng/mL), respectively. However, despite zonulin being 
detected in Western blot, it was not detected with the ELISA kit 
(Figure 3). In comparison, serum from subjects with HP1-1 and 
HP2-2 genotype were measured at a concentration of 67.54 and 
56.41 ng/mL, respectively.
correlations of Measured Protein 
concentrations Using the elisa with 
Metabolic Traits
In a sample of 376 subjects tested using the purchased zonulin 
ELISA, the product was measured in a mean concentration of 
72.2 ± 27.2 ng/mL (mean ± SD), ranging from 17.8 to 207.1 ng/
mL. The ELISA signal was significantly increased in subjects with 
T2D (81.78 ± 25.31 ng/mL) compared with subjects with normal 
glucose tolerance (67.25 ± 25.45 ng/mL, Mann–Whitney U test; 
p = 2.1 × 10−8) or impaired glucose tolerance (71.88 ± 29.36 ng/
mL, p =  0.0017) (Figure  5A). Additionally, lean subjects had 
significantly lower values (65.64 ±  25.23 ng/mL) than subjects 
with overweight (74.20 ±  30.68 ng/mL, p =  0.0082) or obesity 
(76.24 ± 24.17 ng/mL, p = 7.0 × 10−5) (Figure 5B). We observed 
no gender differences or any correlations with age (data not 
shown). The ELISA signal correlated with traits related to glucose 
and lipid metabolism (Spearman’s rank correlation test, adjusted 
for age, sex, and BMI; Table 3). It was positively correlated with 
BMI, HOMA-IR and -IS, and fasting plasma glucose (Table 3). 
Strong correlations were also observed for lipid metabolism 
parameters, such as TG levels, total cholesterol, LDL, and apoli-
poprotein B (Table 3). Correlations were tested for a total of 95 
accessible traits. After Bonferroni correction for multiple testing 
(adjusted value for significance at p <  5.2 ×  10−4), correlations 
for BMI (p = 1.2 × 10−5), fasting glucose (p = 9.0 × 10−6), TG 
(p = 4.2 × 10−10), total cholesterol (p = 3.3 × 10−5), and apolipo-
protein B (p = 2.3 × 10−5) remained statistically significant.
DiscUssiOn
The role of impaired intestinal permeability in metabolic diseases 
including obesity and T2D has recently been acknowledged in 
multiple studies (3, 4, 27). The tight junction regulator zonulin, 
which was identified as pre-HP2 by Tripathi et al. (14), is an estab-
lished circulating marker of intestinal permeability in humans 
(28, 29). Here, we aimed to investigate the relationship between 
intestinal permeability, represented by circulating zonulin, and 
metabolic traits related to obesity and T2D. We set out to measure 
zonulin with a widely used commercially available ELISA kit in a 
metabolically well-characterized cohort of Sorbs from Germany. 
Considering the identity of zonulin as pre-HP2, we also genotyped 
the HP gene in DNA samples from all subjects. The genotype 
frequency of the HP1/1 genotype corresponded to previously 
reported frequencies of 15% in populations of European ancestry 
(16, 17). Assuming that the measured zonulin is identical with 
pre-HP2 as reported previously (13), we expected subjects with 
TaBle 3 | Correlation of ELISA signal with metabolic phenotypes.
non-adjusted adjusted for age,  
sex, BMi
r p-value r p-value
anthropometric trait
Age 0.31 0.55 – –
Sex −0.005 0.93 – –
BMI 0.221 1.2 × 10−5 – –
WHR 0.172 7.3 × 10−4 0.118 2.1 × 10−2
glucose metabolism
Glucose (0 min) 0.294 6.6 × 10−9 0.227 9.0 × 10−6
Glucose (120 min) −0.039 0.45 −0.046 0.38
Insulin (0 min) 0.173 7.7 × 10−4 0.079 0.13
Insulin (120 min) −0.039 0.46 −0.044 0.39
HOMA IR 0.244 2.0 × 10−6 0.149 4.0 × 10−3
HOMA IS −0.243 2.0 × 10−6 −0.145 4.9 × 10−3
lipid metabolism
Triglycerides 0.370 6.5 × 10−14 0.312 4.2 × 10−10
Total cholesterol 0.219 1.5 × 10−5 0.211 3.3 × 10−5
LDL 0.182 3.4 × 10−4 0.160 1.7 × 10−3
HDL −0.136 7.7 × 10−3 −0.063 0.22
Apolipoprotein B 0.247 9.9 × 10−7 0.215 2.3 × 10−5
adipokines
Adiponectin −0.215 2.2 × 10−6 −0.176 5.4 × 10−4
Progranulin 0.151 3.0 × 10−3 0.129 1.1 × 10−2
Vaspin 0.027 0.6 0.05 0.33
Chemerin 0.103 4.3 × 10−2 0.065 0.21
FGF21 0.165 2.1 × 10−3 0.152 4.7 × 10−3
Other
C-reactive protein 0.232 4.0 × 10−6 0.166 1.1 × 10−3
Total protein 0.124 1.5 × 10−2 0.134 8.6 × 10−3
Hemoglobin 0.201 7.4 × 10−5 0.143 5.1 × 10−3
Uric acid 0.176 5.2 × 10−4 0.110 3.1 × 10−2
Bold, significant correlations after adjustment; underlined, significant after Bonferroni 
adjustment for multiple testing (p < 5.2 × 10−4).
r, Spearman’s rank correlation coefficient; p, significance level; BMI, body mass index; 
HDL, high-density lipoprotein; LDL, low-density lipoprotein; WHR, waist-to-hip ratio; 
FGF21, fibroblast growth factor 21; HOMA-IR/IS, Homeostasis Model Assessment 
Insulin Resistance/Insulin Sensitivity.
8
Scheffler et al. Zonulin ELISA Detects Also Properdin
Frontiers in Endocrinology | www.frontiersin.org February 2018 | Volume 9 | Article 22
the HP1/1 genotype to have no detectable, or if taking into 
account cross-reactions, at least significantly lower zonulin levels. 
However, concentrations measured in the HP1/1 homozygous 
subjects were comparable with those found in HP2/2 and HP1/2 
carriers.
The epitope used to generate the capture antibody in the 
zonulin ELISA is based on the sequence GGVLVQPG (AT1001) 
published by Wang et  al. (25) (communication with customer 
support; Immundiagnostik AG, Bensheim, Germany), which 
was initially thought to represent the N-terminal sequence 
of fetal zonulin (25). However, this sequence is not present in 
pre-HP2, which has since been identified to be zonulin (14). The 
discrepancies between the previously reported zonulin sequence 
and the pre-HP2 sequence may be due to intraspecies variability 
associated with a high zonulin mutation rate or due to sequencing 
errors at that time (14). In summary, the commercially available 
competitive ELISA does very likely not detect pre-HP2 or zonulin, 
but rather unknown targets bound by the antibody raised against 
the sequence reported by Wang et al. (25).
Based on database searches, the epitope could correspond 
to Glu-Rich2, a protein which shares seven out of eight amino 
acids. The zonulin/pre-HP2-binding partner CD163 shows 
some conformity with the epitope (30). Our antibody capture 
experiment and subsequent mass spectrometry analysis did not 
provide any evidence for either protein. The most abundant 
protein identified by MS, C3, is evidently an unspecific product 
overshadowing the real targets. Indeed, the respective ELISA 
kit did not detect any complement C3 proteins obtained from 
different suppliers when tested under native and denatured 
conditions, as well as diluted in serum. Also, the same kit did 
not detect recombinant zonulin, mature HP1 or mature HP2. 
Considering the additional MS hits, a few proteins stand 
out, although, without further validation, we interpret these 
data with caution, since only more abundant proteins may 
be identified by MS analysis, while our protein(s) of interest 
may be in low abundance in serum samples and, therefore, 
not identifiable with this approach. The van Willebrand factor 
(vWF, band A, Figure  2) is involved in the intrinsic coagula-
tion pathway and the acute phase response and known to be 
increased in inflammatory bowel disease and bacterial diarrhea 
(31). Inter-alpha-inhibitor heavy chain 4 (band B, Figure 2) is a 
large glycoportein cleaved into smaller fragments by Kallikrein 
which is also involved in the intrinsic coagulation pathway. One 
of these fragments, called urinary trypsin-inhibitor, attenuates 
LPS-induced endothelial barrier dysfunction by upregulation 
of vascular endothelial-cadherin expression (32). Complement 
component 9 (C9, band C, Figure 2) is an important component 
of the membrane attacking complex within the complement 
cascade and is required for complement-mediated lipopolysac-
charide release and outer membrane damage in bacteria (33). 
Protein S100-A8, or Calprotectin (band D, Figure 2), is a cal-
cium- and zinc-binding protein which plays a prominent role in 
the regulation of inflammatory processes and immune response 
(34). However, based on the data presented in Figure  4, our 
most likely candidate(s) should be in the ~50-kDa range, where 
the polyclonal antibody signal was stronger. Therefore, the most 
interesting candidate protein we have identified is properdin 
or factor P (band D, Figure 2), a member of the complement 
alternative pathway that has a molecular weight (53 kDa), within 
the range of those proteins recognized by the Immundiagnostik 
anti-AT1001 polyclonal antibodies (Figures 4A,B) and serum 
levels (~25 ng/mL) (35) similar to the range of detection of the 
kit. Our combined Western blot analysis (Figure 4B) and ELISA 
test confirmed that the polyclonal antibodies raised against 
AT1001 detect properdin among other proteins. However, when 
purified proteins/peptides, including the AT1001 peptide used 
to raise the polyclonal antibodies and which serves as internal 
control in the ELISA kit, were tested by ELISA, they were highly 
underestimated by the test. One possible explanation for these 
results is that zonulin and also properdin are not the main tar-
gets detected by the ELISA; however, the fact that even AT1001 
was underestimated seems to suggest that this hypothesis can-
not entirely explain our results. Alternatively, it is possible that 
tertiary and quaternary (multimers) structure arrangements 
present in sera samples but not in recombinant proteins are nec-
essary in order to properly detect both zonulin and properdin 
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by this ELISA. This is the case and/or that the main target of this 
ELISA is/are additional proteins in the ~50 kDa range present in 
human serum remains to be established.
Once released from neutrophils, T cells, and macrophages in 
response to acute microbial exposure, properdin causes produc-
tion of chemotactic anaphylatoxin C3a and C5a with subsequent 
formation of immune complexes that cause increased endothelial 
permeability (35). Intriguingly, zonulin as pre-HP2 also causes 
generation of C3a and C5a, with subsequent increased vascular 
permeability in several districts, including the lung, with subse-
quent onset of acute lung injury (36). Another striking similarity 
between zonulin and properdin is the fact that both are associated 
with viral respiratory tract infections (37, 38).
Notably, the peptide sequence used for the generation of the 
antibody is also not present in any of the discussed proteins. 
The five proteins mentioned above, including properdin, have 
~50% similarity to this epitope. Zonulin as preHP-2 is a member 
of a larger family of tight junction regulating proteins. Indeed, 
phylogenetic analyses suggest that HPs evolved from mannose-
associated serine protease (MASP), a complement-associated 
protein (like properdin), with their α-chain containing a comple-
ment control protein (CCP) (this domain activates complement 
similar to properdin), while the β-chain is related to chymot-
rypsin-like serine proteases (SP) domain (39, 40). However, the 
SP domain of HP lacks the essential catalytic amino-acid residues 
required for protease function; structure-function analyses have 
implicated this domain in receptor recognition and binding (41). 
Although not an SP, zonulin shares approximately 19% amino-
acid sequence homology with chymotrypsin, and their genes both 
map on chromosome 16. Alignment of the β-chain sequence of 
zonulin to that of several SPs is remarkably consistent except for 
an insertion of 16 residues in the region corresponding to the 
methionyl loop of the SPs. Comparison of the zonulin α–β junc-
tion region with the heavy–light–chain junction of tissue-type 
plasminogen activator strengthens the evolutionary homology 
of zonulin and SPs. The active-site residues typical of the SPs, 
His57 and Ser195, are replaced in zonulin by lysine and alanine, 
respectively. Because of these mutations, during evolution zonu-
lin most likely lost its protease activity despite that zonulin and 
SPs evolved from a common ancestor (18). Therefore, zonulin 
and the SPs represent a striking example of homologous proteins 
with different biological functions but with the common char-
acteristic of complement activation. In addition to zonulin and 
properdin, other members of the MASP family include a series 
of plasminogen-related growth factors [epidermal growth factor 
(EGF), hepatocyte growth factor (HGF), etc.] involved in cell 
growth, proliferation, differentiation and migration, and disrup-
tion of intercellular junctions. In light of these considerations, 
other MASP members identified in our capturing experiments 
in general, and properdin in particular, are intriguing possible 
targets (36).
Analyzing the protein concentrations measured using this 
ELISA in subjects who have been extensively characterized for 
metabolic phenotypes, our data suggest that it is upregulated 
both in diabetic and obese patients. This is in line with previously 
reported findings using this ELISA kit (19–21). Our data show that 
the ELISA target is potentially involved in the lipid metabolism 
by showing in various linear stepwise regression models that tri-
glyceride levels and fasting glucose are the strongest independent 
available variables explaining the observed variance in measured 
protein concentrations (Table S3 in Supplementary Material).
It is important to note that our study, as it has not been initially 
designed to address the question of ELISA specificity, has clear 
limitations. To obtain amounts of isolated protein in the antibody 
capture experiments, we needed to change the experimental 
protocol provided by the manufacturer. We used undiluted 
serum samples instead of a 50-fold dilution, which very likely 
increased the risk of non-specific binding. Yet, we used sera from 
patient that exhibited the highest and the lowest concentrations 
measured by the ELISA kit using the manufacturer’s protocol. 
Thus, any non-specific binding should be detected as equally 
strong bands in the silver-stained gels after the antibody capture 
experiment. Yet, we observed band intensities of affinity purified 
protein that clearly correlated with the concentrations measured 
using the ELISA, in the silver-stained gels (total protein) and in 
the Western blot using the anti-C3-β-chain antibody, indicating 
a specific isolation of proteins recognized by the kit antibody. 
Nevertheless, ELISA results that failed to recognize C3 disputed 
the notion that complement C3 is the target of this kit. Also, we 
have performed this experiment using two different Lot nos. of 
the ELISA, using sera from eight different patients of each high 
and low concentration and obtained the same results.
In conclusion, based on our data we suggest that the 
Immun diagnostik ELISA kit supposedly testing serum zonulin 
(pre-HP2) levels could identify a variety of proteins structurally 
and possibly functionally related to zonulin, suggesting the exist-
ence of a family of zonulin proteins as previously hypothesized 
(42), rather than a single member of permeability-regulating 
proteins. Along these lines, studies that have used this ELISA 
kit for zonulin/preHP2 as a marker for intestinal permeability 
need to be interpreted with these findings in mind (see Table 
S4 in Supplementary Material for a list of publications using 
the respective ELISA kit). Additional studies are necessary to 
establish the primary target proteins (zonulin, properdin, and/or 
other structurally similar proteins) detected by this commercially 
available ELISA.
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